Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Open Orphan Plc ( (GB:HVO) ) has provided an update.
hVIVO plc has announced the publication of a peer-reviewed paper from the world’s first COVID-19 characterisation trial in Nature Communications. The study, conducted in collaboration with Imperial College London and other partners, identified blood-based biomarkers that can distinguish early and late phases of respiratory viral infections, offering potential advancements in infection management. This research, showcasing the utility of human challenge trials, could significantly impact public health by improving early-stage infection diagnosis and patient stratification for antiviral therapies.
More about Open Orphan Plc
hVIVO plc is a fast-growing specialist contract research organization (CRO) that leads in testing infectious and respiratory disease products through human challenge clinical trials. The company offers comprehensive early clinical development services to a large client base, including major global biopharma companies, utilizing its portfolio of human challenge models and specialized drug development capabilities.
YTD Price Performance: -5.64%
Average Trading Volume: 3,636,745
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £151.4M
For an in-depth examination of HVO stock, go to TipRanks’ Stock Analysis page.
